Sperling, Inc. – Trademark Portfolio

Entity Type: 03

Sperling, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 19 (Building Materials) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include MILLION and BULLETCRETE. The owner is based in Huntersville, NC.

5910 Deer Meadows Ln

Huntersville, NC 28078

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MILLION
MILLION
Registered 2006
$
$
Cancelled 2006

Trademark Classifications

Sperling, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

19
Building Materials (1 filing)

Building materials (non-metallic); non-metallic rigid pipes for building

Frequently Asked Questions

How many trademarks does Sperling, Inc. have?

Sperling, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 1 cancelled.

What trademark classes does Sperling, Inc. file in?

Sperling, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 19 (Building Materials). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Sperling, Inc.'s most well-known trademarks?

Sperling, Inc.'s registered trademark portfolio includes well-known marks such as MILLION and BULLETCRETE. These are among 2 currently registered trademarks in the portfolio.

What is Sperling, Inc.'s trademark registration success rate?

Sperling, Inc. has a 50% trademark registration rate, with 2 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.